Previous 10 | Next 10 |
Gainers: SK Telecom (NYSE:SKM) +73%. Genfit (NASDAQ:GNFT) +44%. Bellerophon Therapeutics (NASDAQ:BLPH) +27%. Spruce Biosciences (NASDAQ:SPRB) +25%. AMC Entertainment Holdings (NYSE:AMC) +21%. Stran & Company (NASDAQ:STRNW) +22%. AeroCentury (NYSE:ACY) +19%. cbdMD (NYSE:YCBD) +19%. Net 1 U...
Genfit (NASDAQ:GNFT) +39% inks licensing deal for elafibranor with Ipsen. Spruce Biosciences (NASDAQ:SPRB) +21%. Cerner (NASDAQ:CERN) +17% gains on report Oracle in talks to acquire for about $30B. Bottomline Technologies (NASDAQ:EPAY) +15% agrees to be taken pri...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday! Source: Shutterstock Moving stocks this morning is new analyst coverage, deals, earni...
Gainers: Spruce Biosciences (NASDAQ:SPRB) +30%. Coherus BioSciences (NASDAQ:CHRS) +11%. TPI Composites (NASDAQ:TPIC) +6%. Lyell Immunopharma (NASDAQ:LYEL) +4%. Aquestive Therapeutics (NASDAQ:AQST) +4%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -5%. Leslie's (NASDAQ:LESL) -3%. Rivian Automotiv...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, Chief Financial Officer, will present at the...
Gainers: Kezar Life Sciences KZR +36%, Progenity (NASDAQ:PROG) +28%, GeoVax Labs GOVX +15%, Medicenna Therapeutics (NASDAQ:MDNA) +15%, Amarin AMRN +10%. Losers: Talkspace TALK -37%, OptiNose OPTN -34%, Molecular Partners MOLN...
Spruce Biosciences (NASDAQ:SPRB) appoints Mike Grey as interim Chief Executive Officer, effective immediately. Mr. Grey currently serves as Executive Chairman of the Spruce Board, and will succeed Richard King, who is retiring after a 35-year career in the life sciences industry. Mr. King wil...
Spruce Biosciences (NASDAQ:SPRB): Q3 GAAP EPS of -$0.49 beats by $0.08. Press Release Cash, Cash Equivalents and Investments of $131.3 Million as of September 30, 2021. For further details see: Spruce Biosciences EPS beats by $0.08
Planned Initiation of Phase 2 Programs in Pediatric Classic CAH and Polycystic Ovary Syndrome Late-Stage CAHmelia Program in Adult Classic CAH Expanded to Sites in Australia and Canada Cash, Cash Equivalents and Investments of $131.3 Million as of September 30, 2021 ...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Mike Grey as interim Chief Executive Office...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...